Thomas B Alexander

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2626254/publications.pdf

Version: 2024-02-01

623188 476904 1,202 31 14 29 citations g-index h-index papers 31 31 31 2339 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature, 2018, 562, 373-379.	13.7	236
2	Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood, 2019, 133, 1313-1324.	0.6	172
3	Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discovery, 2021, 11, 1440-1453.	7.7	137
4	Genomic subtyping and therapeutic targeting of acute erythroleukemia. Nature Genetics, 2019, 51, 694-704.	9.4	97
5	Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia. Journal of Clinical Oncology, 2016, 34, 4094-4101.	0.8	93
6	Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. Lancet Oncology, The, 2020, 21, 551-560.	5.1	92
7	International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia. Blood, 2018, 132, 264-276.	0.6	70
8	Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. Blood, 2021, 137, 471-484.	0.6	70
9	The Incidence of Catheter-Associated Venous Thrombosis in Noncritically Ill Children. Hospital Pediatrics, 2015, 5, 59-66.	0.6	50
10	Decreased relapsed rate and treatmentâ€related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials. Cancer, 2017, 123, 3791-3798.	2.0	34
11	Mixedâ€phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force. Cancer, 2020, 126, 593-601.	2.0	32
12	Severe DRESS Syndrome Managed With Therapeutic Plasma Exchange. Pediatrics, 2013, 131, e945-e949.	1.0	27
13	Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Blood, 2019, 134, 285-285.	0.6	24
14	Mixed Phenotype Acute Leukemia: Current Approaches to Diagnosis and Treatment. Current Oncology Reports, 2021, 23, 22.	1.8	21
15	Training pediatric hematologist/oncologists for capacity building in Ethiopia. Pediatric Blood and Cancer, 2020, 67, e28760.	0.8	6
16	Molecular Biology of Childhood Leukemia. Annual Review of Cancer Biology, 2021, 5, 95-117.	2.3	6
17	Venetoclax and Navitoclax in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Blood, 2018, 132, 3966-3966.	0.6	5
18	Metachronous T-Lymphoblastic Lymphoma and Burkitt Lymphoma in a Child With Constitutional Mismatch Repair Deficiency Syndrome. Pediatric Blood and Cancer, 2016, 63, 1454-1456.	0.8	4

#	Article	IF	CITATIONS
19	Training Pediatric Hematologists / Oncologists for Capacity Building in Ethiopia. Blood, 2019, 134, 3423-3423.	0.6	4
20	Genomic Landscape of Pediatric Mixed Phenotype Acute Leukemia. Blood, 2016, 128, 454-454.	0.6	4
21	Opportunities for expanding clinical trial enrollment for relapsed and refractory pediatric acute myeloid leukemia in the United States and Canada. Pediatric Blood and Cancer, 2017, 64, e26632.	0.8	3
22	Therapeutic Targeting of Exportin-1 in Childhood Cancer. Cancers, 2021, 13, 6161.	1.7	3
23	Venetoclax and Navitoclax in Pediatric Patients with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Blood, 2020, 136, 12-13.	0.6	2
24	The Genomic Landscape of Childhood and Adult Acute Erythroid Leukemia. Blood, 2016, 128, 39-39.	0.6	2
25	Acute Leukemia of Ambiguous Lineage: A Comprehensive Survival Analysis Enables Designing New Treatment Strategies. Blood, 2016, 128, 584-584.	0.6	2
26	Successful Erwinia asparaginase oneâ€bag rapid desensitization process inÂaÂpediatric patientÂwith acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2022, 69, e29632.	0.8	2
27	Acute Leukemia Classification Using Transcriptional Profiles From Low-Cost Nanopore mRNA Sequencing. JCO Precision Oncology, 2022, 6, e2100326.	1.5	2
28	Ethiopian paediatric oncology registry progress report: documentation practice improvements at tertiary care centre in Addis Ababa, Ethiopia. Archives of Disease in Childhood, 2021, 106, 1244-1245.	1.0	1
29	Burkitt Lymphoma Genome Sequencing Project (BLGSP): Introduction. Blood, 2016, 128, 1760-1760.	0.6	1
30	Bilineal evolution of a <i>U2AF1</i> -mutated clone associated with acquisition of distinct secondary mutations. Blood Advances, 2021, 5, 5612-5616.	2.5	0
31	Venetoclax in Combination with High-Dose Chemotherapy Is Active and Well-Tolerated in Children with Relapsed or Refractory Acute Myeloid Leukemia. Blood, 2019, 134, 178-178.	0.6	O